Cannet, A. et al. Species identification of phlebotomine sandflies using deep learning and wing interferential pattern (WIP). Sci. Rep. 13, 21389 (2023).
Burza, S., Croft, S. L. & Boelaert, M. Leishmaniasis. Lancet 392, 951–970 (2018).
Bennis, I., De Brouwere, V., Belrhiti, Z., Sahibi, H. & Boelaert, M. Psychosocial burden of localised cutaneous leishmaniasis: a scoping review. BMC Public Health 18, 358 (2018).
Martínez-Valencia, A. J. et al. Clinical and parasitological factors in parasite persistence after treatment and clinical cure of cutaneous leishmaniasis. PLoS Negl. Trop. Dis. 11, e0005713 (2017).
Gidwani, K. et al. Persistence of Leishmania donovani antibodies in past visceral leishmaniasis cases in India. Clin. Vaccin. Immunol. 18, 346–348 (2011).
Akuffo, H. et al. New insights into leishmaniasis in the immunosuppressed. PLoS Negl. Trop. Dis. 12, e0006375 (2018).
Perales-González, A., Pérez-Garza, D. M., Garza-Dávila, V. F. & Ocampo-Candiani, J. Cutaneous leishmaniasis by a needlestick injury, an occupational infection? PLoS Negl. Trop. Dis. 17, 8–11 (2023).
Dahal, P. et al. Visceral leishmaniasis in pregnancy and vertical transmission: a systematic literature review on the therapeutic orphans. PLoS Negl. Trop. Dis. 15, e0009650 (2021).
Pagliano, P. et al. Visceral leishmaniasis in pregnancy: a case series and a systematic review of the literature. J. Antimicrob. Chemother. 55, 229–233 (2005).
Ferreira, T. R. et al. Self-hybridization in Leishmania major. mBio 13, e0285822 (2022).
Inbar, E. et al. Whole genome sequencing of experimental hybrids supports meiosis-like sexual recombination in Leishmania. PLoS Genet. 15, e1008042 (2019).
Sadlova, J. et al. Visualisation of Leishmania donovani fluorescent hybrids during early stage development in the sand fly vector. PLoS ONE 6, e19851 (2011).
Serafim, T. D. et al. Leishmania genetic exchange is mediated by IgM natural antibodies. Nature 623, 149–156 (2023).
Sacks, D. L. The structure and function of the surface lipophosphoglycan on different developmental stages of Leishmania promastigotes. Infect. Agents Dis. 1, 200–206 (1992).
Serafim, T. D. et al. Leishmaniasis: the act of transmission. Trends Parasitol. 37, 976–987 (2021).
Ibarra-Meneses, A. V., Corbeil, A., Wagner, V., Onwuchekwa, C. & Fernandez-Prada, C. Identification of asymptomatic Leishmania infections: a scoping review. Parasit. Vectors 15, 5 (2022).
Molina, R. et al. Role of asymptomatic and symptomatic humans as reservoirs of visceral leishmaniasis in a Mediterranean context. PLoS Negl. Trop. Dis. 14, e0008253 (2020).
Singh, O. P. et al. Xenodiagnosis to evaluate the infectiousness of humans to sandflies in an area endemic for visceral leishmaniasis in Bihar, India: a transmission-dynamics study. Lancet Microbe 2, e23–e31 (2021). Demonstrates through xenodiagnosis that humans in Bihar remain infectious to sandflies, underscoring their central role in visceral leishmaniasis transmission.
Stauch, A. et al. Visceral leishmaniasis in the Indian subcontinent: modelling epidemiology and control. PLoS Negl. Trop. Dis. 5, e1405 (2011).
Bern, C., Courtenay, O. & Alvar, J. Of Cattle, sand flies and men: a systematic review of risk factor analyses for South Asian visceral leishmaniasis and implications for elimination. PLoS Med. 4, e599 (2010). Provides the first systematic review of visceral leishmaniasis risk factors in South Asia, highlighting the importance of cattle, vector exposure and human behaviour for elimination strategies.
Singh, N., Mishra, J., Singh, R. & Singh, S. Animal reservoirs of visceral leishmaniasis in India. J. Parasitol. 99, 64–67 (2013).
Kushwaha, A. K. et al. Dogs as reservoirs for Leishmania donovani, Bihar, India, 2018-2022. Emerg. Infect. Dis. 30, 2604–2613 (2024).
Zijlstra, E. & El-Hassan, A. Leishmaniasis in Sudan. Visceral leishmaniasis. Trans. R. Soc. Trop. Med. Hyg. 95 (Suppl. 1), S28–S58 (2001).
Dantas-Torres, F. Canine leishmaniasis in the Americas: etiology, distribution, and clinical and zoonotic importance. Parasit. Vectors 17, 198 (2024).
Alvar, J. et al. Leishmaniasis worldwide and global estimates of its incidence. PLoS ONE 7, e35671 (2012).
World Health Organization. WHO Collaborating Centre for Clinical Management of Leishmaniasis. Essential Maps. WHO https://leishinfowho-cc55.es/essential-maps/ (2022).
Reithinger, R. et al. Cutaneous leishmaniasis. Lancet Infect. Dis. 7, 581–596 (2007).
Siriwardana, H. V. Y. D. et al. Leishmania donovani and cutaneous leishmaniasis, Sri Lanka. Emerg. Infect. Dis. 13, 476–478 (2007).
Lypaczewski, P. & Matlashewski, G. Leishmania donovani hybridisation and introgression in nature: a comparative genomic investigation. Lancet Microbe 2, e250–e258 (2021).
Lypaczewski, P. et al. Emerging Leishmania donovani lineages associated with cutaneous leishmaniasis, Himachal Pradesh, India, 2023. Emerg. Infect. Dis. 30, 1957 (2024).
Koch, L. K., Kochmann, J., Klimpel, S. & Cunze, S. Modeling the climatic suitability of leishmaniasis vector species in Europe. Sci. Rep. 7, 13325 (2017).
Berry, I. & Berrang-Ford, L. Leishmaniasis, conflict, and political terror: a spatio-temporal analysis. Soc. Sci. Med. 167, 140–149 (2016). Links leishmaniasis incidence to conflict and political violence, showing how instability shapes spatial and temporal patterns of disease.
Aagaard-Hansen, J., Nombela, N. & Alvar, J. Population movement: a key factor in the epidemiology of neglected tropical diseases. Tropical Med. Int. Health 15, 1281–1288 (2010).
Ruiz-Postigo, J. A. et al. Global leishmaniasis surveillance, 2022: assessing trends over the past 10 years. Wkly Epidemiol. Rec. 98, 471–487 (2023).
World Health Organization. Leishmaniasis. WHO https://www.who.int/health-topics/leishmaniasis#tab=tab_1 (accessed 28 October 2025).
Global Burden of Disease Collaborative Network. Global Burden of Disease Study 2023 (GBD 2023) Results. Institute for Health Metrics and Evaluation https://vizhub.healthdata.org/gbd-results/ (2024).
Bailey, F. et al. Cutaneous leishmaniasis and co-morbid major depressive disorder: a systematic review with burden estimates. PLoS Negl. Trop. Dis. 13, e0007092 (2019).
Abadías-Granado, I., Diago, A., Cerro, P. A., Palma-Ruiz, A. M. & Gilaberte, Y. Cutaneous and mucocutaneous leishmaniasis. Actas Dermosifiliogr. 112, 601–618 (2021).
Moya-Salazar, J., Pasco, I. A., Cañari, B. & Contreras-Pulache, H. Cutaneous leishmaniasis associated with the level of poverty of the andean rural population: a five-year single-center study. Electron. J. Gen. Med. 18, em335 (2021).
Wijerathna, T., Gunathilaka, N., Gunawardena, K. & Rodrigo, W. Socioeconomic, demographic and landscape factors associated with cutaneous leishmaniasis in Kurunegala District, Sri Lanka. Parasit. Vectors 13, 244 (2020).
Grifferty, G. et al. Vulnerabilities to and the socioeconomic and psychosocial impacts of the leishmaniases: a review. Res. Rep. Trop. Med. 12, 135–151 (2021). Reviews the socioeconomic and psychosocial burdens of leishmaniasis, emphasizing vulnerabilities that exacerbate disease impact.
Cerf, B. J. et al. Malnutrition as a risk factor for severe visceral leishmaniasis. J. Infect. Dis. 156, 1030–1033 (1987).
Anstead, G. M. et al. Malnutrition alters the innate immune response and increases early visceralization following Leishmania donovani infection. Infect. Immun. 69, 4709 (2001).
Alvar, J., den Boer, M. & Dagne, D. A. Towards the elimination of visceral leishmaniasis as a public health problem in east Africa: reflections on an enhanced control strategy and a call for action. Lancet Glob. Health 9, e1763–e1769 (2021).
Pan American Health Organization. Leishmaniasis: Epidemiological Report on the Region of the Americas. Pan American Health Organization https://iris.paho.org/handle/10665.2/59155 (2023).
Salomón, O. D., Feliciangeli, M. D., Quintana, M. G., Afonso, M. M. D. S. & Rangel, E. F. Lutzomyia longipalpis urbanisation and control. Mem. Inst. Oswaldo Cruz 110, 831–846 (2015).
de Araújo, V. E. M. et al. Relative risk of visceral leishmaniasis in Brazil: a spatial analysis in urban area. PLoS Negl. Trop. Dis. 7, e2540 (2013).
Van der Auwera, G. et al. Surveillance of leishmaniasis cases from 15 European centres, 2014 to 2019: a retrospective analysis. Eurosurveillance 27, 2002028 (2022).
Rocha, R., Pereira, A. & Maia, C. Non-endemic leishmaniases reported globally in humans between 2000 and 2021 — a comprehensive review. Pathogens 11, 921 (2022).
McIlwee, B. E., Weis, S. E. & Hosler, G. A. Incidence of endemic human cutaneous leishmaniasis in the United States. JAMA Dermatol. 154, 1032–1039 (2018).
Curtin, J. M. & Aronson, N. E. Leishmaniasis in the United States: emerging issues in a region of low endemicity. Microorganisms 9, 578 (2021).
Chapman, L. A. C. et al. Age trends in asymptomatic and symptomatic Leishmania donovani infection in the Indian subcontinent: a review and analysis of data from diagnostic and epidemiological studies. PLoS Negl. Trop. Dis. 12, e0006803 (2018). Synthesizes diagnostic and epidemiological data to reveal age-related differences in asymptomatic versus symptomatic L. donovani infection.
Carvalho, A. M., Amorim, C. F., Barbosa, J. L. S., Lago, A. S. & Carvalho, E. M. Age modifies the immunologic response and clinical presentation of American tegumentary leishmaniasis. Am. J. Tropical Med. Hyg. 92, 1173–1177 (2015).
Terefe, Y., Afera, B., Bsrat, A. & Syoum, Z. Distribution of human leishmaniasis (VL) and its associated risk factors, in Metemma, Ethiopia. Epidemiol. Res. Int. https://doi.org/10.1155/2015/630812 (2015).
Cloots, K. et al. Male predominance in reported visceral leishmaniasis cases: nature or nurture? A comparison of population-based with health facility-reported data. PLoS Negl. Trop. Dis. 14, e0007995 (2020).
Lockard, R. D., Wilson, M. E. & Rodríguez, N. E. Sex-related differences in immune response and symptomatic manifestations to infection with Leishmania species. J. Immunol. Res. 2019, 4103819 (2019).
Lezama-Dávila, C. M., Isaac-Márquez, A. P., Barbi, J., Oghumu, S. & Satoskar, A. R. 17Beta-estradiol increases Leishmania mexicana killing in macrophages from DBA/2 mice by enhancing production of nitric oxide but not pro-inflammatory cytokines. Am. J. Tropical Med. Hyg. 76, 1125–1127 (2014).
Lezama-Dávila, C. M. et al. Role of phosphatidylinositol-3-kinase-γ (PI3Kγ)-mediated pathway in 17β-estradiol-induced killing of L. mexicana in macrophages from C57BL/6 mice. Immunol. Cell Biol. 86, 539–543 (2008).
Zhang, H., Zhao, J., Wang, P. & Qiao, Z. Effect of testosterone on Leishmania donovani infection in macrophages. Parasitol. Res. 87, 674–676 (2001).
Jayakumar, B., Murthy, N., Misra, K. & Burza, S. “It’s just a fever”: gender based barriers to care-seeking for visceral leishmaniasis in highly endemic districts of India: a qualitative study. PLoS Negl. Trop. Dis. 13, e0007457 (2019). Identifies gender-based barriers to visceral leishmaniasis care in India, showing how women’s health needs are delayed or overlooked.
Alvar, J. et al. The relationship between leishmaniasis and AIDS: the second 10 years. Clin. Microbiol. Rev. 21, 334–359 (2008).
Mohebali, M. & Yimam, Y. Prevalence estimates of human immunodeficiency virus (HIV) infection among visceral leishmaniasis infected people in Northwest Ethiopia: a systematic review and meta-analysis. BMC Infect. Dis. 20, 214 (2020).
Burza, S. et al. HIV and visceral leishmaniasis coinfection in Bihar, India: an underrecognized and underdiagnosed threat against elimination. Clin. Infect. Dis. 59, 552–555 (2014).
Singh, O. P. et al. Visceral leishmaniasis-human immunodeficiency virus-coinfected patients are highly infectious to sandflies in an endemic area in India. J. Infect. Dis. 229, 1909–1912 (2024). Establishes that patients with HIV-visceral leishmaniasis co-infection are exceptionally infectious to sandflies, amplifying community transmission risk.
Diro, E. et al. Atypical manifestations of visceral leishmaniasis in patients with HIV in north Ethiopia: a gap in guidelines for the management of opportunistic infections in resource poor settings. Lancet Infect. Dis. 15, 122–129 (2015).
Burza, S. et al. AmBisome monotherapy and combination AmBisome–miltefosine therapy for the treatment of visceral leishmaniasis in patients coinfected with human immunodeficiency virus in India: a randomized open-label, parallel-arm, phase 3 trial. Clin. Infect. Dis. 75, 1423–1432 (2022).
Van Griensven, J., Mohammed, R., Ritmeijer, K., Burza, S. & Diro, E. Tuberculosis in visceral leishmaniasis-human immunodeficiency virus coinfection: an evidence gap in improving patient outcomes? Open Forum Infect. Dis. 5, ofy059 (2018).
Busutti, M. et al. Updated diagnosis and graft involvement for visceral leishmaniasis in kidney transplant recipients: a case report and literature review. Infection 51, 507–518 (2023).
Van Griensven, J., Carrillo, E., López-Vélez, R., Lynen, L. & Moreno, J. Leishmaniasis in immunosuppressed individuals. Clin. Microbiol. Infect. 20, 286–299 (2014).
Cloots, K. et al. Visceral leishmaniasis-HIV coinfection as a predictor of increased Leishmania transmission at the village level in Bihar, India. Front. Cell Infect. Microbiol. 11, 604117 (2021). Demonstrates at the village level that HIV co-infection predicts increased visceral leishmaniasis transmission, highlighting a critical challenge for elimination programmes.
Mondal, D. et al. Quantifying the infectiousness of post-kala-azar dermal leishmaniasis toward sand flies. Clin. Infect. Dis. 69, 251–258 (2019).
Musa, A. M. et al. Paromomycin and miltefosine combination as an alternative to treat patients with visceral leishmaniasis in Eastern Africa: a randomized, controlled, multicountry trial. Clin. Infect. Dis. 76, e1177–e1185 (2023).
Alvar, J., Yactayo, S. & Bern, C. Leishmaniasis and poverty. Trends Parasitol. 22, 552–557 (2006).
Kumar, V. U. et al. The possible role of selected vitamins and minerals in the therapeutic outcomes of leishmaniasis. Biol. Trace Elem. Res. 201, 1672–1688 (2023).
Cota, G., Erber, A. C., Schernhammer, E. & Simões, T. C. Inequalities of visceral leishmaniasis case-fatality in Brazil: a multilevel modeling considering space, time, individual and contextual factors. PLoS Negl. Trop. Dis. 15, e0009567 (2021).
Bharati, K. Human genetic polymorphism and leishmaniasis. Infect. Genet. Evol. 98, 105203 (2022).
Wilson, J. et al. Prognostic prediction models for clinical outcomes in patients diagnosed with visceral leishmaniasis: protocol for a systematic review. BMJ Open 13, e075597 (2023).
Ivens, A. C. et al. The genome of the kinetoplastid parasite, Leishmania major. Science 309, 436–442 (2005).
Lypaczewski, P. et al. A complete Leishmania donovani reference genome identifies novel genetic variations associated with virulence. Sci. Rep. 8, 16549 (2018).
Lachaud, L. et al. Constitutive mosaic aneuploidy is a unique genetic feature widespread in the Leishmania genus. Microbes Infect. 16, 61–66 (2014).
Franssen, S. U. et al. Global genome diversity of the Leishmania donovani complex. eLife 9, e51243 (2020).
Hadermann, A. et al. Genome diversity of Leishmania aethiopica. Front. Cell Infect. Microbiol. 13, 1147998 (2023).
Patino, L. H. et al. Revisiting the heterogeneous global genomic population structure of Leishmania infantum. Microb. Genom. 7, 000640 (2021).
Black, J. A., Reis-Cunha, J. L., Cruz, A. K. & Tosi, L. R. O. Life in plastic, it’s fantastic! How Leishmania exploit genome instability to shape gene expression. Front. Cell Infect. Microbiol. 13, 1102462 (2023).
Camacho, E. et al. Leishmania mitochondrial genomes: maxicircle structure and heterogeneity of minicircles. Genes 10, 758 (2019).
Rossi, M. et al. Type I interferons induced by endogenous or exogenous viral infections promote metastasis and relapse of leishmaniasis. Proc. Natl Acad. Sci. USA 114, 4987–4992 (2017).
Ives, A. et al. Leishmania RNA virus controls the severity of mucocutaneous leishmaniasis. Science 331, 775–778 (2011).
Hartley, M. A. et al. Leishmaniavirus-dependent metastatic leishmaniasis is prevented by blocking IL-17A. PLoS Pathog. 12, e1005852 (2016).
Rahmanipour, M. et al. Effect of Leishmania RNA virus 2 on virulence factors and cytokines gene expression in a human macrophage infected with Leishmania major: a preliminary study. Exp. Parasitol. 246, 108459 (2023).
Zangger, H. et al. Leishmania aethiopica field isolates bearing an endosymbiontic dsRNA virus induce pro-inflammatory cytokine response. PLoS Negl. Trop. Dis. 8, e2836 (2014).
Kaye, P. & Scott, P. Leishmaniasis: complexity at the host-pathogen interface. Nat. Rev. Microbiol. 9, 604–615 (2011).
van Zandbergen, G. et al. Cutting edge: neutrophil granulocyte serves as a vector for Leishmania entry into macrophages. J. Immunol. 173, 6521–6525 (2004).
Lee, S. H. et al. Dermis resident macrophages orchestrate localized ILC2 eosinophil circuitries to promote non-healing cutaneous leishmaniasis. Nat. Commun. 14, 7852 (2023).
Ueno, N. & Wilson, M. E. Receptor-mediated phagocytosis of Leishmania: implications for intracellular survival. Trends Parasitol. 28, 335–344 (2012).
Dermine, J. F., Scianimanico, S., Prive, C., Descoteaux, A. & Desjardins, M. Leishmania promastigotes require lipophosphoglycan to actively modulate the fusion properties of phagosomes at an early step of phagocytosis. Cell Microbiol. 2, 115–126 (2000).
Gluenz, E., Ginger, M. L. & McKean, P. G. Flagellum assembly and function during the Leishmania life cycle. Curr. Opin. Microbiol. 13, 473–479 (2010).
Jara, M. et al. Transcriptional shift and metabolic adaptations during Leishmania quiescence using stationary phase and drug pressure as models. Microorganisms 10, 97 (2022).
Dirkx, L. et al. Long-term hematopoietic stem cells trigger quiescence in Leishmania parasites. PLoS Pathog. 20, e1012181 (2024). Although macrophages and other classical phagocytes are generally considered the major host cells supporting Leishmania replication, this study demonstrates that haematopoietic stem cells also harbour large numbers of parasites and may facilitate the development of a quiescent state.
Kloehn, J. et al. Identification of metabolically quiescent Leishmania mexicana parasites in peripheral and cured dermal granulomas using stable isotope tracing imaging mass spectrometry. mBio 12, e00129-21 (2021).
Silverman, J. M. & Reiner, N. E. Leishmania exosomes deliver preemptive strikes to create an environment permissive for early infection. Front. Cell Infect. Microbiol. 1, 26 (2011).
Dong, G., Filho, A. L. & Olivier, M. Modulation of host-pathogen communication by extracellular vesicles (EVs) of the protozoan parasite Leishmania. Front. Cell Infect. Microbiol. 9, 100 (2019). As in cancer, the role of exosomes in intercellular communication during leishmaniasis is an important area of research.
de Souza, W. & Barrias, E. S. Membrane-bound extracellular vesicles secreted by parasitic protozoa: cellular structures involved in the communication between cells. Parasitol. Res. 119, 2005–2023 (2020).
Heyde, S. et al. CD11c-expressing Ly6C+CCR2+ monocytes constitute a reservoir for efficient Leishmania proliferation and cell-to-cell transmission. PLoS Pathog. 14, e1007374 (2018).
Rosazza, T. et al. Dynamic imaging reveals surface exposure of virulent Leishmania amastigotes during pyroptosis of infected macrophages. J. Cell Sci. 134, jcs242776 (2020).
Volkmar, K. et al. Investigating pyroptosis as a mechanism of L. major cell-to-cell spread in the human BLaER1 infection model. Mol. Microbiol. 121, 453–469 (2024).
Baars, I. et al. Leishmania major drives host phagocyte death and cell-to-cell transfer depending on intracellular pathogen proliferation rate. JCI Insight 8, e169020 (2023).
Stogerer, T. et al. Leishmania donovani exploits tunneling nanotubes for dissemination and propagation of B cell activation. Microbiol. Spectr. 11, e0509622 (2023).
Parkash, P. et al. Safety and reactogenicity of a controlled human infection model of sand fly transmitted cutaneous leishmaniasis. Nat. Med. 30, 3150–3162 (2024). This article reports the safety and efficacy of a new human challenge model of sandfly-transmitted cutaneous leishmaniasis, developed to facilitate the testing of new prophylactic interventions.
Evans, T. G. & Pearson, R. D. Clinical and immunological responses following accidental inoculation of Leishmania donovani. Trans. R. Soc. Trop. Med. Hyg. 82, 854–856 (1988).
Amare, G. et al. First report of cutaneous leishmaniasis caused by Leishmania donovani in Ethiopia. Parasit. Vectors 16, 457 (2023).
Siriwardana, Y. et al. Trends in recently emerged Leishmania donovani induced cutaneous leishmaniasis, Sri Lanka, for the first 13 years. Biomed. Res. Int. 2019, 4093603 (2019).
Tuon, F. F. et al. Treatment of New World cutaneous leishmaniasis — a systematic review with a meta-analysis. Int. J. Dermatol. 47, 109–124 (2008).
Nylen, S. & Eidsmo, L. Tissue damage and immunity in cutaneous leishmaniasis. Parasite Immunol. 34, 551–561 (2012).
Ridley, D. S. & Ridley, M. J. The evolution of the lesion in cutaneous leishmaniasis. J. Pathol. 141, 83–96 (1983).
Masoudzadeh, N. et al. Molecular signatures of anthroponotic cutaneous leishmaniasis in the lesions of patients infected with Leishmania tropica. Sci. Rep. 10, 16198 (2020).
Amorim, C. et al. Multinomic profiling of cutaneous leishmaniasis infections reveals microbiota-driver mechanisms underlying disease severity. Sci. Transl. Med. 15, eadh1469 (2023).
Kurban, A. K., Malak, J. A., Farah, F. S. & Chaglassian, H. T. Histopathology of cutaneous leishmaniasis. Arch. Dermatol. 93, 396–401 (1966).
Dey, N. S. et al. Early reduction in PD-L1 expression predicts faster treatment response in human cutaneous leishmaniasis. J. Clin. Investig. 131, e142765 (2021). A first demonstration that immune-checkpoint molecules impact treatment outcome in leishmaniasis, paving the way for the development of host-directed therapies.
Bahrami, F. et al. Blood transcriptional profiles distinguish different clinical stages of cutaneous leishmaniasis in humans. Mol. Immunol. 149, 165–173 (2022).
Scott, P. & Novais, F. O. Cutaneous leishmaniasis: immune responses in protection and pathogenesis. Nat. Rev. Immunol. 16, 581–592 (2016).
Dey, R. et al. Production of leishmanin skin test antigen from Leishmania donovani for future reintroduction in the field. Nat. Commun. 14, 7028 (2023).
Singh, S. S. et al. Increased amphiregulin expression by CD4+ T cells from individuals with asymptomatic Leishmania donovani infection. Clin. Transl. Immunol. 11, e1396 (2022).
Hermida, M. D., de Melo, C. V. B., Lima, I. D. S., Oliveira, G. G. S. & Dos-Santos, W. L. C. Histological disorganization of spleen compartments and severe visceral leishmaniasis. Front. Cell Infect. Microbiol. 8, 394 (2018).
Kaye, P. M. & Beattie, L. Lessons from other diseases: granulomatous inflammation in leishmaniasis. Semin. Immunopathol. 38, 249–260 (2016).
Santos-Oliveira, J. R. et al. Evidence that lipopolisaccharide may contribute to the cytokine storm and cellular activation in patients with visceral leishmaniasis. PLoS Negl. Trop. Dis. 5, e1198 (2011).
Costa, C. H. N., Chang, K. P., Costa, D. L. & Cunha, F. V. M. From infection to death: an overview of the pathogenesis of visceral leishmaniasis. Pathogens 12, 969 (2023). An in-depth review of the clinical features associated with visceral leishmaniasis.
Nylen, S. & Sacks, D. Interleukin-10 and the pathogenesis of human visceral leishmaniasis. Trends Immunol. 28, 378–384 (2007).
Edwards, C. L. et al. A molecular signature for IL-10-producing Th1 cells in protozoan parasitic diseases. JCI Insight 8, e169362 (2023).
Kumar, R. et al. Type I interferons suppress anti-parasitic immunity and can be targeted to improve treatment of visceral leishmaniasis. Cell Rep. 30, 2512–2525.e9 (2020).
Bern, C. et al. Loss of leishmanin skin test antigen sensitivity and potency in a longitudinal study of visceral leishmaniasis in Bangladesh. Am. J. Trop. Med. Hyg. 75, 744–748 (2006).
Kirstein, O. D. et al. Minimally invasive microbiopsies: a novel sampling method for identifying asymptomatic, potentially infectious carriers of Leishmania donovani. Int. J. Parasitol. 47, 609–616 (2017).
Doehl, J. S. P. et al. Skin parasite landscape determines host infectiousness in visceral leishmaniasis. Nat. Commun. 8, 57 (2017). The first quantitative analysis of parasite distribution in the skin during experimental visceral leishmaniasis, with implications for our understanding of transmission dynamics.
Stark, D., Pett, S., Marriott, D. & Harkness, J. Post-kala-azar dermal leishmaniasis due to Leishmania infantum in a human immunodeficiency virus type 1-infected patient. J. Clin. Microbiol. 44, 1178–1180 (2006).
Mukhopadhyay, D., Dalton, J. E., Kaye, P. M. & Chatterjee, M. Post kala-azar dermal leishmaniasis: an unresolved mystery. Trends Parasitol. 30, 65–74 (2014).
Sengupta, R., Roy, M., Dey, N. S., Kaye, P. M. & Chatterjee, M. Immune dysregulation and inflammation causing hypopigmentation in post kala-azar dermal leishmaniasis: partners in crime? Trends Parasitol. 39, 822–836 (2023).
de Vrij, N. et al. Persistent T cell unresponsiveness associated with chronic visceral leishmaniasis in HIV-coinfected patients. Commun. Biol. 7, 524 (2024).
Takele, Y. et al. Immunological factors, but not clinical features, predict visceral leishmaniasis relapse in patients co-infected with HIV. Cell Rep. Med. 3, 100487 (2022).
Fontes, J. L. M. et al. An integrated analysis of the structural changes and gene expression of spleen in human visceral leishmaniasis with and without HIV coinfection. PLoS Negl. Trop. Dis. 18, e0011877 (2024).
Reinaldo, L. G. C. et al. The spleen is the graveyard of CD4+ cells in patients with immunological failure of visceral leishmaniasis and AIDS. Parasit. Vectors 17, 132 (2024).
Farias Amorim, C. et al. Localized skin inflammation during cutaneous leishmaniasis drives a chronic, systemic IFN-γ signature. PLoS Negl. Trop. Dis. 15, e0009321 (2021).
Fantecelle, C. H. et al. Transcriptomic landscape of skin lesions in cutaneous leishmaniasis reveals a strong CD8+ T cell immunosenescence signature linked to immunopathology. Immunology 164, 754–765 (2021).
Novais, F. O., Amorim, C. F. & Scott, P. Host-directed therapies for cutaneous leishmaniasis. Front. Immunol. 12, 660183 (2021).
Boaventura, V. S. et al. Human mucosal leishmaniasis: neutrophils infiltrate areas of tissue damage that express high levels of Th17-related cytokines. Eur. J. Immunol. 40, 2830–2836 (2010).
Scorza, B. M., Carvalho, E. M. & Wilson, M. E. Cutaneous manifestations of human and murine leishmaniasis. Int. J. Mol. Sci. 18, 1296 (2017).
Christensen, S. M. et al. Host and parasite responses in human diffuse cutaneous leishmaniasis caused by L. amazonensis. PLoS Negl. Trop. Dis. 13, e0007152 (2019).
Bryceson, A. D. Diffuse cutaneous leishmaniasis in Ethiopia. I. The clinical and histological features of the disease. Trans. R. Soc. Trop. Med. Hyg. 63, 708–737 (1969).
Halstead, S. B., Mahalingam, S., Marovich, M. A., Ubol, S. & Mosser, D. M. Intrinsic antibody-dependent enhancement of microbial infection in macrophages: disease regulation by immune complexes. Lancet Infect. Dis. 10, 712–722 (2010).
Silva-Barrios, S., Charpentier, T. & Stager, S. The deadly dance of B cells with trypanosomatids. Trends Parasitol. 34, 155–171 (2018).
Gardinassi, L. G. et al. Clinical severity of visceral leishmaniasis is associated with changes in immunoglobulin G fc N-glycosylation. mBio 5, e01844 (2014).
Blackwell, J. M. Structure and function of the natural-resistance-associated macrophage protein (Nramp1), a candidate protein for infectious and autoimmune disease susceptibility. Mol. Med. Today 2, 205–211 (1996).
Sacks, D. & Noben-Trauth, N. The immunology of susceptibility and resistance to Leishmania major in mice. Nat. Rev. Immunol. 2, 845–858 (2002).
Fakiola, M. et al. Common variants in the HLA-DRB1-HLA-DQA1 HLA class II region are associated with susceptibility to visceral leishmaniasis. Nat. Genet. 45, 208–213 (2013).
Blackwell, J. M., Fakiola, M. & Castellucci, L. C. Human genetics of Leishmania infections. Hum. Genet. 139, 813–819 (2020). Essential reading for an in-depth critique of host genetic factors affecting the outcome of leishmaniasis.
Meazzi, S. et al. Gut microbiota and lymphocyte subsets in canine leishmaniasis. Front. Vet. Sci. 9, 868967 (2022).
Gimblet, C. et al. Cutaneous leishmaniasis induces a transmissible dysbiotic skin microbiota that promotes skin inflammation. Cell Host Microbe 22, 13–24.e4 (2017). An important study describing how the microbiota impacts disease development in cutaneous leishmaniasis, with implications for treatment.
Lovins, V. et al. Staphylococcus aureus promotes strain-dependent immunopathology during cutaneous leishmaniasis through induction of IL-1β. Cell Rep. 44, 115624 (2025).
Dhaliwal, A. et al. Donor acquired visceral leishmaniasis following liver transplantation. Frontline Gastroenterol. 12, 690–694 (2021).
Antinori, S., Cascio, A., Parravicini, C., Bianchi, R. & Corbellino, M. Leishmaniasis among organ transplant recipients. Lancet Infect. Dis. 8, 191–199 (2008).
Riera, C. et al. Asymptomatic infection by Leishmania infantum in blood donors from the Balearic Islands (Spain). Transfusion 48, 1383–1389 (2008).
Rodrigues, W. F. et al. A critical review of the applicability of serological screening for leishmaniasis in blood banks in Brazil. J. Parasit. Dis. 45, 109–117 (2021).
de Oliveira França, A. et al. Leishmania infection in blood donors: a new challenge in leishmaniasis transmission? PLoS ONE 13, e0198199 (2018).
World Health Organization. Leishmaniasis (WHO, 2023).
van Griensven, J. & Diro, E. Visceral leishmaniasis. Infect. Dis. Clin. North Am. 26, 309–322 (2012).
Hurissa, Z. et al. Clinical characteristics and treatment outcome of patients with visceral leishmaniasis and HIV co-infection in northwest Ethiopia. Tropical Med. Int. Health 15, 848–855 (2010).
Kumar, A. et al. Post kala-azar dermal leishmaniasis in the Indian sub-continent: challenges and strategies for elimination. Front. Immunol. 14, 1236952 (2023).
Cunningham, J. et al. A global comparative evaluation of commercial immunochromatographic rapid diagnostic tests for visceral leishmaniasis. Clin. Infect. Dis. 55, 1312–1319 (2012). Well-designed study comparing rapid diagnostic tests for visceral leishmaniasis in different continents.
Boelaert, M. et al. Rapid tests for the diagnosis of visceral leishmaniasis in patients with suspected disease. Cochrane Database Syst. Rev. 2014, CD009135 (2014). Meta-analysis of the diagnostic performance of rapid diagnostic tests for visceral leishmaniasis.
van Griensven, J. & Diro, E. Visceral leishmaniasis: recent advances in diagnostics and treatment regimens. Infect. Dis. Clin. North Am. 33, 79–99 (2019).
European Centre for Disease Prevention and Control. Surveillance, Prevention and Control of Leishmaniases in the European Union and Its Neighbouring Countries. European Centre for Disease Prevention and Control https://www.ecdc.europa.eu/en/publications-data/surveillance-prevention-control-leishmaniases-European-Union-and-neighbouring-countries (2022).
Kumari, D., Perveen, S., Sharma, R. & Singh, K. Advancement in leishmaniasis diagnosis and therapeutics: an update. Eur. J. Pharmacol. 910, 174436 (2021).
Diro, E. et al. Visceral leishmaniasis and HIV coinfection in East Africa. PLoS Negl. Trop. Dis. 8, e2869 (2014).
Reimão, J. Q., Coser, E. M., Lee, M. R. & Coelho, A. C. Laboratory diagnosis of cutaneous and visceral leishmaniasis: current and future methods. Microorganisms 8, 1632 (2020).
Henten, S. V. an et al. Evaluation of the CL detect rapid test in Ethiopian patients suspected for cutaneous leishmaniasis. PLoS Negl. Trop. Dis. 16, e0010143 (2022).
van Henten, S. et al. Evaluation of less invasive sampling tools for the diagnosis of cutaneous leishmaniasis. Open Forum Infect. Dis. 11, ofae113 (2024).
Taslimi, Y. et al. A novel non-invasive diagnostic sampling technique for cutaneous leishmaniasis. PLoS Negl. Trop. Dis. 11, e0005750 (2017).
Vijayakumar, S. et al. A review of non-invasive samples and tools in kala-azar diagnosis and test of cure. Exp. Parasitol. 259, 108713 (2024).
Ibarra-Meneses, A. V. et al. Loop-mediated isothermal amplification allows rapid, simple and accurate molecular diagnosis of human cutaneous and visceral leishmaniasis caused by Leishmania infantum when compared to PCR. Microorganisms 9, 610 (2021).
Mukhtar, M. et al. Sensitive and less invasive confirmatory diagnosis of visceral leishmaniasis in Sudan using loop-mediated isothermal amplification (LAMP). PLoS Negl. Trop. Dis. 12, e0006264 (2018).
Adams, E. R. et al. Development and evaluation of a novel loop-mediated isothermal amplification assay for diagnosis of cutaneous and visceral leishmaniasis. J. Clin. Microbiol. 56, e00386-18 (2018).
van Dijk, N. J. et al. Simplified molecular diagnosis of visceral leishmaniasis: Laboratory evaluation of miniature direct-on-blood PCR nucleic acid lateral flow immunoassay. PLoS Negl. Trop. Dis. 18, e0011637 (2024).
Vallur, A. C. et al. Development and comparative evaluation of two antigen detection tests for visceral leishmaniasis. BMC Infect. Dis. 15, 384 (2015).
Singh, O. P. & Sundar, S. Visceral leishmaniasis elimination in India: progress and the road ahead. Expert Rev. Anti Infect. Ther. 20, 1381–1388 (2022).
World Health Organization. Control of the Leishmaniasis. WHO Technical Report Series 949: Report of a Meeting of the WHO Expert Committee on the Control of Leishmaniasis, Geneva 22-26 March 2010 (WHO, 2010). WHO report providing a comprehensive overview of leishmaniasis control strategies. Updated WHO guidelines are expected for 2026.
World Health Organization. Control of Neglected Tropical Diseases. WHO https://www.who.int/teams/control-of-neglected-tropical-diseases/leishmaniasis/vector-control (accessed 28 October 2025).
Singh, O. P., Hasker, E., Boelaert, M. & Sundar, S. Elimination of visceral leishmaniasis on the Indian Subcontinent. Lancet Infect. Dis. 16, e304–e309 (2017).
Sundar, S., Singh, O. P. & Chakravarty, J. Visceral leishmaniasis elimination targets in India, strategies for preventing resurgence. Expert Rev. Anti Infect. Ther. 16, 805–812 (2018).
Elnaiem, D. E. A. et al. Outdoor residual insecticide spraying (ODRS), a new approach for the control of the exophilic vectors of human visceral leishmaniasis: phlebotomus orientalis in East Africa. PLoS Negl. Trop. Dis. 14, e0008774 (2020).
Pan American Health Organization. Manual of Procedures for Leishmaniasis Surveillance and Control in the Region of the Americas 2nd edn (PAHO, 2024).
Montenegro Quiñonez, C. A., Runge-Ranzinger, S., Rahman, K. M. & Horstick, O. Effectiveness of vector control methods for the control of cutaneous and visceral leishmaniasis: a meta-review. PLoS Negl. Trop. Dis. 15, e0009309 (2021).
Centers for Disease Control and Prevention. Preventing Leishmaniasis. CDC https://www.cdc.gov/leishmaniasis/prevention/index.html (accessed 28 October 2025).
Abdoli, A. et al. Effect of rodent control program on incidence of zoonotic cutaneous leishmaniasis, Iran. Emerg. Infect. Dis. 30, 1447–1449 (2024).
Veysi, A. et al. Rodenticide comparative effect of Klerat® and zinc phosphide for controlling zoonotic cutaneous leishmaniasis in Central Iran. Iran. J. Parasitol. 11, 471–479 (2016).
González, U. et al. Vector and reservoir control for preventing leishmaniasis (Review). Cochrane Database Syst. Rev. 2015, CD008736 (2015).
Karmakar, S. et al. Preclinical validation of a live attenuated dermotropic Leishmania vaccine against vector transmitted fatal visceral leishmaniasis. Commun. Biol. 4, 929 (2021).
Younis, B. M. et al. A randomized double-blind phase IIb trial to evaluate the efficacy of ChAd63-KH for the treatment of post kala-azar dermal leishmaniasis. Mol. Ther. Methods Clin. Dev. 32, 101310 (2024).
Saha, S., Vashishtha, S., Kundu, B. & Ghosh, M. In-silico design of an immunoinformatics based multi-epitope vaccine against Leishmania donovani. BMC Bioinformatics 23, 319 (2022).
da Cruz Freire, J. E. et al. Molecular and immunological properties of a chimeric glycosyl hydrolase 18 based on immunoinformatics approaches: a design of a new anti-Leishmania vaccine. ACS Pharmacol. Transl. Sci. 8, 78–96 (2025).
Malvolti, S., Malhame, M., Mantel, C. F., Le Rutte, E. A. & Kaye, P. M. Human leishmaniasis vaccines: use cases, target population and potential global demand. PLoS Negl. Trop. Dis. 15, e0009742 (2021). Paper providing the rationale for vaccine development for leishmaniasis.
Mohan, S. et al. Estimating the global demand curve for a leishmaniasis vaccine: a generalisable approach based on global burden of disease estimates. PLoS Negl. Trop. Dis. 16, e0010471 (2022).
Kaye, P. M. et al. Vaccine value profile for leishmaniasis. Vaccine 41 (Suppl. 2), S153–S175 (2023).
Sundar, S. et al. Failure of pentavalent antimony in visceral leishmaniasis in India: report from the center of the Indian epidemic. Clin. Infect. Dis. 31, 1104–1107 (2000). Study clearly demonstrating the increasing treatment failure rates with antimonials in India.
Sundar, S. et al. Comparison of short-course multidrug treatment with standard therapy for visceral leishmaniasis in India: an open-label, non-inferiority, randomised controlled trial. Lancet 377, 477–486 (2011). Pivotal trial identifying several safe and effective combination treatment regimens.
World Health Organization/SEARO. Regional Strategic Framework for Accelerating and Sustaining Elimination of Kala-azar in the South-East Asia Region: 2022–2026 (WHO, 2022).
National Guideline on Kala-azar Elimination Program (Ministry of Health of Nepal, 2019).
National Guideline for Kala-azar Case Management (Ministry of Health of Bangladesh, 2013).
Goyal, V. et al. Field safety and effectiveness of new visceral leishmaniasis treatment regimens within public health facilities in Bihar, India. PLoS Negl. Trop. Dis. 12, e0006830 (2018). Study providing field data on several new visceral leishmaniasis treatment regimens.
Alves, F. et al. Recent development of visceral leishmaniasis treatments: successes, pitfalls, and perspectives. Clin. Microbiol. Rev. 31, e00048-18 (2018).
Carnielli, J. et al. Natural resistance of Leishmania infantum to miltefosine contributes to the low efficacy in the treatment of visceral leishmaniasis in Brazil. Am. J. Trop. Med. Hyg. 101, 789–794 (2019).
Romero, G. A. S. et al. Efficacy and safety of available treatments for visceral leishmaniasis in Brazil: a multicenter, randomized, open label trial. PLoS Negl. Trop. Dis. 11, e0005706 (2017).
Goyal, V. et al. Long-term incidence of relapse and post-kala-azar dermal leishmaniasis after three different visceral leishmaniasis treatment regimens in Bihar, India. PLoS Negl. Trop. Dis. 14, e0008429 (2020).
Diro, E. et al. A randomized trial of AmBisome monotherapy and AmBisome and miltefosine combination to treat visceral leishmaniasis in HIV co-infected patients in Ethiopia. PLoS Negl. Trop. Dis. 13, e0006988 (2019).
World Health Organization. Expert Committee on the Control of Leishmaniases. WHO Guideline for the Treatment of Visceral Leishmaniasis in HIV Co-Infected Patients in East Africa and South-East Asia (WHO, 2022). Revised WHO guidance on the management of visceral leishmaniasis in individuals with HIV co-infection in East Africa and the Indian subcontinent.
Zijlstra, E. E., Alves, F., Rijal, S., Arana, B. & Alvar, J. Post-kala-azar dermal leishmaniasis in the Indian subcontinent: a threat to the South-East Asia Region Kala-azar Elimination Programme. PLoS Negl. Trop. Dis. 11, e0005877 (2017).
Ramesh, V., Katara, G. K., Verma, S. & Salotra, P. Miltefosine as an effective choice in the treatment of post-kala-azar dermal leishmaniasis. Br. J. Dermatol. 165, 411–414 (2011).
Sundar, S. et al. Oral miltefosine treatment in children with mild to moderate Indian visceral leishmaniasis. Pediatr. Infect. Dis. J. 22, 434–438 (2003).
Sundar, S. et al. A phase II, non-comparative randomised trial of two treatments involving liposomal amphotericin B and miltefosine for post-kala-azar dermal leishmaniasis in India and Bangladesh. PLoS Negl. Trop. Dis. 18, e0012242 (2024).
Musa, A. M. et al. The natural history of Sudanese post-kala-azar dermal leishmaniasis: clinical, immunological and prognostic features. Ann. Trop. Med. Parasitol. 96, 765–772 (2002).
Manual for the Diagnosis and Treatment of Leishmaniasis (Ministry of Health of the Republic of Sudan, 2017).
Younis, B. M. et al. Safety and efficacy of paromomycin/miltefosine/liposomal amphotericin B combinations for the treatment of post-kala-azar dermal leishmaniasis in Sudan: a phase II, open label, randomized, parallel arm study. PLoS Negl. Trop. Dis. 17, e0011780 (2023).
Blum, J. et al. LeishMan recommendations for treatment of cutaneous and mucosal leishmaniasis in travelers, 2014. J. Travel. Med. 21, 116–129 (2014). Useful guidance for settings systematically performing species identification to guide treatment.
World Health Organization. Manual for Case Management of Cutaneous Leishmaniasis in the WHO Eastern Mediterranean Region (WHO, 2014).
Garza-Tovar, T. F., Sacriste-Hernández, M. I., Juárez-Durán, E. R. & Arenas, R. An overview of the treatment of cutaneous leishmaniasis. Fac. Rev. 9, 28 (2020).
Heras-Mosteiro, J. et al. Interventions for Old World cutaneous leishmaniasis. Cochrane Database Syst. Rev. 11, CD005067 (2017). Systematic review of interventions for cutaneous leishmaniasis in Asia, Africa and Europe.
Tesfa, D. et al. Clinical pattern and treatment outcome of cutaneous leishmaniasis in two hospitals in Bahir Dar, Ethiopia (2017-2021). J. Infect. Dev. Ctries 16, 26S–34S (2022).
Henten, S. V. an et al. Community-based treatment of cutaneous leishmaniasis using cryotherapy and miltefosine in Southwest Ethiopia: the way forward? Front. Med. 10, 1196063 (2023).
Pan American Health Organization. Guideline for the Treatment of Leishmaniasis in the Americas. Second Edition (PAHO, 2022).
Saenz, R. E., Paz, H. & Berman, J. D. Efficacy of ketoconazole against Leishmania braziliensis panamensis cutaneous leishmaniasis. Am. J. Med. 89, 147–155 (1990).
Navin, T. R., Arana, B. A., Arana, F. E., Berman, J. D. & Chajón, J. F. Placebo-controlled clinical trial of sodium stibogluconate (Pentostam) versus ketoconazole for treating cutaneous leishmaniasis in Guatemala. J. Infect. Dis. 165, 528–534 (1992).
González, U. et al. Interventions for American cutaneous and mucocutaneous leishmaniasis. Cochrane Database Syst. Rev. https://doi.org/10.1002/14651858.CD004834.pub2 (2009).
Pan American Health Organization. Interactive Atlas of Leishmaniasis in the Americas: Clinical Aspects and Differential Diagnosis (PAHO, 2020).
Chulay, J. D., Spencer, H. C. & Mugambi, M. Electrocardiographic changes during treatment of leishmaniasis with pentavalent antimony (sodium stibogluconate). Am. J. Trop. Med. Hyg. 34, 702–709 (1985).
Thakur, C. P. Harmful effect of high stibogluconate treatment of kala-azar in India. Trans. R. Soc. Trop. Med. Hyg. 80, 672–673 (1986).
Ortega-Carnicer, J., Alcázar, R., la Torre, M., De & Benezet, J. Pentavalent antimonial-induced torsade de pointes. J. Electrocardiol. 30, 143–145 (1997).
Den Boer, M. et al. Safety and effectiveness of short-course AmBisome in the treatment of post–kala-azar dermal leishmaniasis: a prospective cohort study in Bangladesh. Clin. Infect. Dis. 67, 667–675 (2018).
Jensen, G. M. The care and feeding of a commercial liposomal product: liposomal amphotericin B (AmBisome®). J. Liposome Res. 27, 173–179 (2017).
Ghosh, S. et al. Inadequacy of 12-week miltefosine treatment for Indian post-kala-azar dermal leishmaniasis. Am. J. Trop. Med. Hyg. 93, 767–769 (2015).
Pijpers, J., den Boer, M. L., Essink, D. R. & Ritmeijer, K. The safety and efficacy of miltefosine in the long-term treatment of post-kala-azar dermal leishmaniasis in South Asia – a review and meta-analysis. PLoS Negl. Trop. Dis. 13, e0007173 (2019).
Sundar, S., Singh, J., Dinkar, A. & Agrawal, N. Safety and effectiveness of miltefosine in post–kala-azar dermal leishmaniasis: an observational study. Open Forum Infect. Dis. 10, ofad231 (2023).
World Health Organization. Advisory Committee on Safety of Medicinal Products (ACSoMP): Measures to Minimize the Risk of Ocular Adverse Events With Miltefosine (WHO, 2023).
Garapati, P. et al. Knowledge, stigma, health seeking behaviour and its determinants among patients with post kalaazar dermal leishmaniasis, Bihar, India. PLoS ONE 13, e0203407 (2018).
Nair, M., Kumar, P., Pandey, S., Kazmi, S. & Moreto-planas, L. Quality of life perceptions amongst patients co-infected with visceral leishmaniasis and HIV: a qualitative study from Bihar, India. PLoS ONE 15, e0227911 (2020).
Veeri, R. B. et al. Assessment of quality of life using WHOQOL-BREF in patients with visceral leishmaniasis. Health Qual. Life Outcomes 17, 53 (2019).
Govil, D., Sahoo, H., Pedgaonkar, S. P., Das, K. C. & Lhungdim, H. Assessing knowledge, attitudes, and preventive practices related to kala-a: a study of Rural Madhepura, Bihar, India. Am. J. Tropical Med. Hyg. 98, 857–863 (2018).
Alemayehu, M., Wubshet, M., Mesfin, N. & Gebayehu, A. Effect of health care on quality of life among human immunodeficiency virus infected adults with and without visceral leishmaniasis in northwest Ethiopia: a longitudinal follow-up study. Am. J. Tropical Med. Hyg. 98, 1476–1645 (2018).
Boelaert, M. et al. The poorest of the poor: a poverty appraisal of households affected by visceral leishmaniasis in Bihar, India. Tropical Med. Int. Health 14, 639–644 (2009).
Meheus, F. et al. The economic burden of visceral leishmaniasis in Sudan: an assessment of provider and household costs. Am. J. Tropical Med. Hyg. 89, 1146–1153 (2013).
Sunyoto, T., Boelaert, M. & Meheus, F. Understanding the economic impact of leishmaniasis on households in endemic countries: a systematic review. Expert Rev. Anti Infect. Ther. 17, 57–69 (2019). Study summarizing the knowledge of the economic aspects of leishmaniasis.
Sunyoto, T. et al. ‘Kala-Azar is a dishonest disease’: community perspectives on access barriers to visceral leishmaniasis (Kala-Azar) diagnosis and care in Southern Gadarif, Sudan. Am. J. Tropical Med. Hyg. 98, 1091–1101 (2018).
Adhikari, S. & Maskay, N. Economic cost and consequences of kala-azar in Danusha and Mahottari districts of Nepal. Indian J. Commun. Med. 30, 121–125 (2005).
Adhikari, S. R., Maskay, N. M. & Sharma, B. P. Paying for hospital-based care of Kala-azar in Nepal: assessing catastrophic, impoverishment and economic consequences. Health Policy Plan. 24, 129–139 (2009).
Rijal, S., Koirala, S., Van der Stuyft, P. & Boelaert, M. The economic burden of visceral leishmaniasis for households in Nepal. Trans. R. Soc. Trop. Med. Hyg. 100, 838–841 (2006).
Uranw, S., Meheus, F., Baltussen, R., Rijal, S. & Boelaert, M. The household costs of visceral leishmaniasis care in South-eastern Nepal. PLoS Negl. Trop. Dis. 7, e2062 (2013).
Sharma, D. et al. The economic impact of visceral leishmaniasis on housholds in Bangladesh. Tropical Med. Int. Health 11, 757–764 (2006).
Ozaki, M. et al. Economic consequences of post-kala-azar dermal leishmaniasis in a rural Bangladeshi community. Am. J. Tropical Med. Hyg. 85, 528–534 (2011).
de Carvalho, I., Peixoto, H., Romero, G. & de Oliveira, M. Cost of visceral leishmaniasis care in Brazil. Tropical Med. Int. Health 22, 1579–1589 (2017).
Ahluwalia, I. B. et al. Visceral leishmaniasis: consequences of a neglected disease in a Bangladeshi community. Am. J. Tropical Med. Hyg. 69, 624–628 (2003).
World Health Organization. Kala-Azar in India – Progress and Challenges Towards its Elimination as a Public Health Problem. WHO https://www.who.int/publications/i/item/who-wer9626-267-279 (2021).
Gill, N., Pandey, D. & Roy, N. Kala-azar in India – progress and challenges towards its elimination as a public health problem. Wkly Epidemiol. Rec. 26, 267–279 (2021).
Alvar, J., Beca-Martínez, M. T., Argaw, D., Jain, S. & Aagaard-Hansen, J. Social determinants of visceral leishmaniasis elimination in Eastern Africa. BMJ Glob. Health 8, e012638 (2023).
Tessema, S. B. et al. The economic burden of visceral leishmaniasis and barriers to accessing healthcare in Tigray, North Ethiopia: a field based study. PLoS Negl. Trop. Dis. 18, e0012423 (2024).
Pires, M., Wright, B., Kaye, P. M., da Conceição, V. & Churchill, R. C. The impact of leishmaniasis on mental health and psychosocial well-being: a systematic review. PLoS ONE 14, e0223313 (2019).
Nuwangi, H. et al. Stigma associated with cutaneous and mucocutaneous leishmaniasis: a systematic review. PLoS Negl. Trop. Dis. 17, e0011818 (2023). Review providing a comprehensive overview of studies on stigma related to cutaneous leishmaniasis.
Refai, W. et al. Cutaneous leishmaniasis in Sri Lanka: effect on quality of life. Int. J. Dermatol. 176, 139–148 (2017).
Vares, B. et al. Quality of life in patients with cutaneous leishmaniasis. Arch. Iran. Med. 16, 474–477 (2013).
Doni, S. et al. Health-related quality of life of adults with cutaneous leishmaniasis at ALERT Hospital, Addis Ababa, Ethiopia. PLoS Negl. Trop. Dis. 17, e0011196 (2023).
Hu, R. V. P. F. et al. Body location of “new world” cutaneous leishmaniasis lesions and its impact on the quality of life of patients in Suriname. PLoS Negl. Trop. Dis. 14, e0008759 (2020).
Toledo, A. J. et al. Assessment of the quality of life of patients with cutaneous leishmaniasis in Belo Horizonte, Brazil, 2009-2010. A pilot study. Trans. R. Soc. Trop. Med. Hyg. 107, 335–336 (2013).
Pinart, M. et al. Interventions for American cutaneous and mucocutaneous leishmaniasis (review). Cochrane Database Syst. Rev. 8, CD004834 (2020). Systematic review of interventions for cutaneous leishmaniasis in the Americas.
Erber, A. C. et al. Patients’ preferences of cutaneous leishmaniasis treatment outcomes: findings from an international qualitative study. PLoS Negl. Trop. Dis. 14, e0007996 (2020).
Castro, M. et al. Involving patients in drug development for Neglected Tropical Diseases (NTDs): a qualitative study exploring and incorporating preferences of patients with cutaneous leishmaniasis into Target Product Profile development. PLoS Negl. Trop. Dis. 18, e0011975 (2024).
World Health Organization. A Road Map for Neglected Tropical Diseases 2021-2030. Report by the Director-General (WHO, 2021). Pivotal WHO guidance informing national neglected disease strategies.
Garlapati, R., Iniguez, E., Sera, T. D., Mishra, P. K. & Rooj, B. Towards a sustainable vector- control strategy in the post kala-azar elimination era. Front. Cell Infect. Microbiol. 11, 641632 (2021).
Lawyer, P., Sundar, S. & Petersen, C. A. Domestic mammals as reservoirs for Leishmania donovani on the Indian subcontinent: possibility and consequences on elimination. Transbound. Emerg. Dis. 69, 268–277 (2023).
Pal, B. et al. Barriers to the effective management and prevention of post kala-azar dermal leishmaniasis (PKDL) in the Indian subcontinent. Med. J. Armed Forces India 79, 500–505 (2023).
Rock, K. S., Chapman, L. A. C., Dobson, A. P., Adams, E. R. & Hollingsworth, T. D. The hidden hand of asymptomatic infection hinders control of neglected tropical diseases: a modeling analysis. Clin. Infect. Dis. 78, S175–S182 (2024).
Cloots, K. et al. Monitoring of Leishmania transmission in the postelimination phase: the potential of serological surveys. Int. J. Infect. Dis. 147, 108153 (2024).
World Health Organization. Strategic Framework for the Elimination of Visceral Leishmaniasis as a Public Health Problem in Eastern Africa 2023-2030 (WHO, 2024).
World Health Organization. New Framework Launched to Eliminate Visceral Leishmaniasis in Eastern Africa. WHO https://www.who.int/news/item/12-06-2024-new-framework-launched-to-eliminate-visceral-leishmaniasis-in-eastern-africa (2024).
World Health Organization. Target Product Profile for a Diagnostic Test to Confirm Visceral Leishmaniasis (WHO, 2024).
Castro, M. D. M. et al. Cutaneous leishmaniasis treatment and therapeutic outcomes in special populations: a collaborative retrospective study. PLoS Negl. Trop. Dis. 17, e0011029 (2023).
Thacker, S. G. et al. CpG ODN D35 improves the response to abbreviated low-dose pentavalent antimonial treatment in non-human primate model of cutaneous leishmaniasis. PLoS Negl. Trop. Dis. 14, e0008050 (2020).
de Souza, W. & Weaver, S. Effects of climate change and human activities on vector-borne diseases. Nat. Rev. Microbiol. 22, 476–491 (2024).
Hage, R. et al. Spatiotemporal relationship between agriculture, livestock, deforestation, and visceral leishmaniasis in Brazilian legal Amazon. Sci. Rep. 14, 21542 (2024).
Carvalho, B. M. et al. A climatic suitability indicator to support Leishmania infantum surveillance in Europe: a modelling study. Lancet Regional Health Eur. 43, 100971 (2024).
Musa, A. et al. Sodium stibogluconate (SSG) & paromomycin combination compared to SSG for visceral leishmaniasis in East Africa: a randomised controlled trial. PLoS Negl. Trop. Dis. 6, e1674 (2012).
Sundar, S., Chakravarty, J., Agarwal, D., Rai, M. & Murray, H. W. Single-dose liposomal amphotericin B for visceral leishmaniasis in India. N. Engl. J. Med. 362, 504–512 (2010). Trial demonstrating the efficacy of single-dose amphotericin B in India, which has subsequently been used as first-line treatment option in national programmes on the Indian subcontinent.
Rahman, R. et al. Safety and efficacy of short course combination regimens with AmBisome, miltefosine and paromomycin for the treatment of visceral leishmaniasis (VL) in Bangladesh. PLoS Negl. Trop. Dis. 11, e0005635 (2017).
Sundar, S. et al. Efficacy of miltefosine in the treatment of visceral leishmaniasis in India after a decade of use. Clin. Infect. Dis. 55, 543–550 (2012).
Bern, C. et al. Liposomal amphotericin B for the treatment of visceral leishmaniasis. Clin. Infect. Dis. 43, 917–924 (2006).
World Health Organization. WHO Expert Committee on the Control of the Leishmaniases & World Health Organization. Control of the Leishmaniases: Report of a Meeting of the WHO Expert Committee on the Control of Leishmaniases (WHO, 2010).
Guideline for Diagnosis, Treatment and Prevention of Leishmaniasis in Ethiopia (Ministry of Health of Ethiopia, 2013).
